Skip to main content

Sobi to take direct responsibility for Orfadin in the US, Canada and Latin America

Press Release   •   Dec 20, 2013 09:11 GMT

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has decided to take direct responsibility for Orfadin® in the US, Canada, and Latin America by terminating the current distributorship agreement with their partner Rare Disease Therapeutics, Inc (RDT). Financial details were not disclosed.

"Our US subsidiary is ready to consistently and safely supply Orfadin to patients throughout the Americas, and we look forward to bringing a global perspective to partnering with Genetic and Metabolic physicians in serving the Tyrosinemia community in these territories," said Geoffrey McDonough, Sobi's CEO.

The distributorship will transfer to Sobi on 1 April 2014 for the US and Canada, and on 1 January 2015 for Latin America.

For more information - not for publication
Media relations
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
oskar.bosson@sobi.com

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: +46 8 697 20 00
jorgen.winroth@sobi.com

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.

 

Attached Files

PDF document